NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
3/8 — Basic
CORTEF ACETATE (hydrocortisone acetate) by Pfizer is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Approved for atopic dermatitis.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cortef Acetate is a topical corticosteroid containing hydrocortisone acetate, indicated for atopic dermatitis as an anti-inflammatory agent. It provides direct local administration to affected areas, reducing inflammation and pruritus associated with dermatologic conditions. The drug works by suppressing immune-mediated inflammatory responses in the skin.
Pre-Launch
Pre-launch status indicates early-stage commercialization planning; limited team size currently with expected growth post-approval.
Mechanism of Action
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Clinical Trials (1)
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Started Mar 2016
16 enrolled
Healthy
Worked on CORTEF ACETATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.